NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

AZTR

Azitra Inc

Jun 30 • 04:00PM ET

0.2614

Dollar change +0.0013
Percentage change 0.50	%

Healthcare • Biotechnology • USA • AMEX

Peers: ANAB FATE VYGR AKTX TVRD ARWR ORMP PULM ARMP BCRX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.46	Insider Own	0.82%	Shs Outstand	17.23M	Perf Week	12.09%
Market Cap	4.50M	Forward P/E	-	EPS next Y	-0.66	Insider Trans	0.00%	Shs Float	17.09M	Perf Month	-3.54%
Enterprise Value	1.76M	PEG	-	EPS next Q	-0.21	Inst Own	3.10%	Short Float	3.84%	Perf Quarter	-14.30%
Income	-9.10M	P/S	450.39	EPS this Y	63.29%	Inst Trans	-18.25%	Short Ratio	0.24	Perf Half Y	-35.93%
Sales	0.01M	P/B	0.89	EPS next Y	24.14%	ROA	-152.02%	Short Interest	0.66M	Perf YTD	-38.57%
Book/sh	0.29	P/C	1.40	EPS next 5Y	35.36%	ROE	-208.50%	52W High	12.00 -97.82%	Perf Year	-92.56%
Cash/sh	0.19	P/FCF	-	EPS past 3/5Y	56.64% -	ROIC	-196.73%	52W Low	0.23 15.77%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-59.15% -	Gross Margin	-5909.81%	Volatility	8.60% 8.60%	Perf 5Y	-
Dividend TTM	-	EV/Sales	176.39	EPS Y/Y TTM	87.57%	Oper. Margin	-148318.41%	ATR (14)	0.02	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.02	Sales Y/Y TTM	-98.69%	Profit Margin	-121372.83%	RSI (14)	46.01	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.02	EPS Q/Q	94.66%	SMA20	-2.42%	Beta	-1.58	Target Price	3.00
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	-7.58%	Rel Volume	0.26	Prev Close	0.26
Employees	12	LT Debt/Eq	0.05	Earnings	May 13 AMC	SMA200	-32.45%	Avg Volume	2.78M	Price	0.26
IPO	Jun 16, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	736,488	Change	0.50%

Jun-17-25 08:02AM	Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome (PR Newswire)
Jun-10-25 08:33AM	Azitra, Inc. Announces Presentation at the 2025 BIO International Convention (PR Newswire)
May-28-25 08:33AM	Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash (PR Newswire)
May-14-25 04:05PM	Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash (PR Newswire)
May-13-25 05:06PM	Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates (PR Newswire)
08:33AM	Loading…
Apr-25-25 08:33AM	Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025 (PR Newswire)
Apr-24-25 04:05PM	Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline (PR Newswire)
Mar-12-25 08:33AM	Azitra to Present at Microbiome Times Partnering Forum (PR Newswire)
Feb-24-25 08:30AM	Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates (PR Newswire)
Feb-04-25 02:20PM	Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock (PR Newswire) +16.34%
Feb-03-25 09:05AM	Azitra, Inc. to Present at the BIO CEO & Investor Conference (PR Newswire) +15.08%
Jan-27-25 04:05PM	Azitra, Inc. to Present at The Microcap Conference (PR Newswire) -6.64% +20.35%
Jan-15-25 08:30AM	Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock (PR Newswire) -39.03%
Jan-14-25 04:05PM	Azitra Announces Proposed Public Offering of Common Stock (PR Newswire) -26.75%
Nov-12-24 05:05PM	Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates (PR Newswire)
09:00AM	Loading…
Oct-29-24 09:00AM	Azitra to Present at BIO-Europe 2024 (Business Wire)
Oct-11-24 09:00AM	Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit (Business Wire)
Sep-24-24 08:00AM	Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress (Business Wire)
Sep-18-24 09:00AM	Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors (Business Wire) +5.82%
Sep-06-24 04:30PM	Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-28-24 08:30AM	Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome (Business Wire)
Aug-22-24 09:00AM	Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors (Business Wire) +11.14%
Aug-20-24 04:15PM	Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome (Business Wire) +5.98%
Aug-12-24 06:23PM	Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates (Business Wire)
Jul-25-24 05:57PM	CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering (Business Wire) -9.65%
Jul-23-24 09:20PM	Azitra, Inc. Announces Pricing of $10.0 Million Public Offering (Business Wire) +206.79% -76.46%
08:00AM	Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents (Business Wire)
Jun-27-24 04:05PM	Azitra, Inc. Announces Reverse Stock Split (Business Wire) +12.72% -30.15%
May-31-24 08:00AM	Azitra, Inc. Announces Presentation at the 2024 BIO International Convention (Business Wire)
May-17-24 08:00AM	Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting (Business Wire) -8.22%
08:00AM	Loading…
May-10-24 08:00AM	Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting (Business Wire) -13.08%
May-09-24 05:00PM	Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates (Business Wire)
Apr-22-24 04:30PM	Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting (Business Wire) +18.77%
Apr-18-24 04:15PM	Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024 (Business Wire) -5.10%
Mar-15-24 04:15PM	Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates (Business Wire)
Feb-16-24 04:05PM	Azitra, Inc. Announces Closing of Public Offering (Business Wire) +6.01% +5.79%
Feb-13-24 10:09PM	Azitra, Inc. Announces Pricing of Public Offering (Business Wire) -24.33% -73.91%
Jan-16-24 09:00AM	Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US (Business Wire) +32.50%
Jan-03-24 09:00AM	Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference (Business Wire) +11.42%
Nov-14-23 04:30PM	Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates (Business Wire)
Oct-16-23 08:00AM	Azitra to Present at the ThinkEquity Conference (Business Wire) +7.59%
Aug-29-23 08:00AM	Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-14-23 04:05PM	Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates (PR Newswire) -6.52%
Jul-19-23 04:05PM	Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors (PR Newswire)
Jul-11-23 04:05PM	Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer (PR Newswire)
Jun-21-23 06:46PM	Azitra, Inc. Announces Closing of Initial Public Offering (PR Newswire) +9.62%
Jun-15-23 07:04PM	Azitra, Inc. Announces Pricing of Initial Public Offering (PR Newswire)

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KDT VENTURES FUND I, LP	Former Director	Sep 13 '24	Proposed Sale	0.58	9,730	5,648		Sep 16 05:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZTR

Azitra Inc

Upgrade your FINVIZ experience